Patent Term Extended Under 35 U.S.C.   156(d)(5)

   On October 9, 1998, patent owner Pharmacia & Upjohn, S.p.A., filed an
application under 35 U.S.C.    156(d)(5) for interim extension of the
term of U.S. Patent No. 4,229,449. The patent claims the active
ingredient roboxetine mesylate. The application indicates that a New
Drug Application for the human drug product roboxetine mesylate has been
filed and is currently undergoing a regulatory review before the Food
and Drug Administration for permission to market or use the product
commercially.

   Review of the application indicates that except for permission to market
or use the product commercially, the subject patent would be eligible
for an extension of the patent term under 35 U.S.C.    156. Accordingly,
on February 22, 1999, an interim extension under 35 U.S.C.    156(d)(5)
of the term of U.S. Patent No. 4,229,449 was granted for a period of one
year from the original expiration date of the patent, January 8, 1999.